Medicare

First Opinion By Matthew Cooper

Medicare policy on antirejection drugs imperils kidney transplants

First Opinion By Michael Altman

We ventured into the Medicare Part D drug plan forest — and got lost

First Opinion By Allyson Y. Schwartz

Deadline looms to stop the Health Insurance Tax — but Congress has been there before

Pharmalot By Ed Silverman

Lawmakers ask HHS for greater oversight of patient assistance programs

Pharmalot By Ed Silverman

As Trump looks overseas for drug pricing ideas, one expert says France has some useful approaches

First Opinion By Rajalakshmi Iyer and James Regan

Protect patient access to drug infusions administered in physician offices

First Opinion By Liz Helms

Policymakers are taking the wrong approach to health care reform

First Opinion By Robert McLean and Gary LeRoy

Medicare’s new primary care payment rule is good news for patients

First Opinion By Ira Byock and Eric Walsh

Hopewell House hospice has closed. You should care about that

Health By Lev Facher — STAT and Liz Goodwin — Boston Globe

Elizabeth Warren’s health care evolution has earned her friends on the left, but foes in her home state

Pharmalot By Ed Silverman

More Americans can’t afford prescriptions and most think Trump isn’t doing enough to help

First Opinion By Seema Verma

Seema Verma: CMS’s ‘expanded pathway’ for new antibiotics can help fight antimicrobial resistance

First Opinion By Shawn Morris

Medicare’s Shared Savings Program results should have made headlines. It got a ‘collective shrug’ instead

Pharmalot By Ed Silverman

Pharmalittle: Congress struggles with drug pricing bill; in Utah, pleas on social media for insulin

First Opinion By Nav Persaud and Danielle Martin

It’s time for Canada to embrace universal pharmacare and protect drug coverage from corporate erosion

Pharmalot By Ed Silverman

Two patient charities settle allegations of helping drug makers pay Medicare kickbacks

Pharmalot By Ed Silverman

Pharmalittle: Biogen resurrects an Alzheimer’s drug; last-minute settlement in a big opioid trial

Biotech By Nicholas Florko

This small biotech is suing the Trump administration to get its drug covered

Pharmalot By Ed Silverman

Pharmalittle: House progressives seek to change Pelosi bill; shortage of a critical cancer drug for kids

Pharmalot By Ed Silverman

Most Americans back various ideas to lower drug costs, but some fear impeachment will get in the way

Pharmalot By Ed Silverman

Avanir to pay $116 million to settle bribery charges, while two docs and former sales reps are indicted

Health By Associated Press

Feds take down alleged Medicare gene test fraud that peddled cheek swabs

Pharmalot By Ed Silverman

Pharmalittle: More countries restrict heartburn meds; Novartis battles Belgium over gene therapy for a toddler

Pharmalot By Ed Silverman

Generic makers claim Medicare Part D plans crowd them out, hurting seniors

Politics By Nicholas Florko and Lev Facher

Our 9 biggest questions about Nancy Pelosi’s drug pricing bill

Pharmalot By Ed Silverman

Pharmalittle: Senators ask FTC to probe pharma mergers; is the Purdue settlement blood money?

Pharmalot By Ed Silverman

Medicare Part D rebates ‘substantially’ reduced drug spending, but not enough to offset price hikes

Pharmalot By Ed Silverman

Pharmalittle: Mallinckrodt mulls restructuring as opioid trial nears; the next FDA commissioner will be …

Politics By Nicholas Florko

Study: A cap on Medicare drug costs helps a small few — a lot